NovaBridge (NBP) CMO Dennis Andrew Exercises Shares, Sells 8,209

What Happened
Dennis Phillip Andrew, NovaBridge Biosciences' Chief Medical Officer, exercised/converted 23,695 shares (derivative conversion) on 2026-09-17. On the same day 10,302 of those shares were disposed with no cash proceeds (reported at $0.00, consistent with withholding or conversion mechanics). On 2026-09-18 he sold 8,209 shares in an open-market transaction at $0.71 per share for total proceeds of $5,828 (the filing notes a converted ADS sales price of $1.6247). Based on the reported transactions, 23,695 acquired − 10,302 withheld − 8,209 sold = 5,184 ordinary shares appear to remain from this conversion (filing does not state a final "amount owned" explicitly).

Key Details

• Transaction dates: 2026-09-17 (exercise/conversion and disposition of 10,302 shares), 2026-09-18 (open-market sale of 8,209 shares).
• Prices and proceeds: open-market sale at $0.71/share for $5,828 total; one disposal shown at $0.00 (likely tax withholding/cashless conversion). Filing also reports ADS-converted sale price of $1.6247 for the sale.
• Shares from conversion: 23,695 ordinary shares acquired via exercise/conversion on 9/17; net retained from this event appears to be 5,184 ordinary shares (see note above). The filing does not list a single "Amount Owned Following Reported Transaction" line that sums total holdings.
• Notable footnotes: the company uses ADSs (10 ADSs = 23 ordinary shares); RSUs are used by the company (each RSU represents a right to receive one ADS), and a 164,840 RSU grant from 6/17/2024 with a multi-year vesting schedule is referenced. The filing shows certain reported securities represented as ADS quantities.
• Timeliness: Form 4 was filed on 2026-09-21 for transactions on 9/17–9/18; this appears to be within the required two business days and therefore timely.

Context

• These were derivative conversions/vest-related transactions (not a fresh open‑market purchase). The $0.00 disposal commonly reflects shares withheld or surrendered to cover tax obligations on vested awards; the follow-up open-market sale supplied modest cash proceeds (~$5.8k).
• For retail investors: exercise/vesting events often reflect compensation vesting rather than a manager buying more stock; purchases are generally a stronger bullish signal than routine vesting/withholding sales.